Patents by Inventor Bheemashankar A. Kulkarni
Bheemashankar A. Kulkarni has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220402927Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.Type: ApplicationFiled: August 9, 2022Publication date: December 22, 2022Inventors: Sujay BASU, Sachin THORAT, Yogesh SHEJUL, Anil PANMAND, Meena PATEL, Goraksha KHOSE, Rajesh BONAGIRI, Dinesh BARAWKAR, Bheemashankar KULKARNI, Kasim MOOKHTIAR
-
Patent number: 11407758Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).Type: GrantFiled: January 4, 2019Date of Patent: August 9, 2022Assignee: IMPETIS BIOSCIENCES LTD.Inventors: Sujay Basu, Sachin Thorat, Yogesh Shejul, Anil Panmand, Meena Patel, Goraksha Khose, Rajesh Bonagiri, Dinesh Barawkar, Bheemashankar Kulkarni, Kasim Mookhtiar
-
Patent number: 11142603Abstract: The present application relates to a commercially viable process for the preparation of Patiromer, a crosslinked polymer. More particularly the present application relates to a commercially viable process for the preparation of Patiromer sorbitex calcium, an active ingredient useful in the treatment of hyperkalemia.Type: GrantFiled: May 9, 2019Date of Patent: October 12, 2021Assignee: Solara Active Pharma Sciences LimitedInventors: Sivadas Anand, Sarita Mohan Pavaskar, Bheemashankar Kulkarni
-
Patent number: 11098026Abstract: Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.Type: GrantFiled: March 13, 2018Date of Patent: August 24, 2021Assignee: IMPETIS BIOSCIENCES LIMITEDInventors: Nadim Shaikh, Mahesh Thakkar, Shailesh Shinde, Manoj Joshi, Keshav Naik, Amit Bhalerao, Mayur Mukim, Debnath Bhuniya, Bheemashankar Kulkarni, Kasim Mookhtiar
-
Publication number: 20210070764Abstract: The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them. Formula (I) wherein D represents a tricyclic ring system selected from: Formula (II) or Formula (III).Type: ApplicationFiled: January 4, 2019Publication date: March 11, 2021Inventors: Sujay BASU, Sachin THORAT, Yogesh SHEJUL, Anil PANMAND, Meena PATEL,, Goraksha KHOSE, Rajesh BONAGIRI, Dinesh BARAWKAR, Bheemashankar KULKARNI, Kasim MOOKHTIAR
-
Publication number: 20200339577Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.Type: ApplicationFiled: July 6, 2020Publication date: October 29, 2020Inventors: Dinesh BARAWKAR, Anil M DESHPANDE, Santosh PATIL, Yogesh WAMAN, Anil PANMAND, Dilip JADHAV, Bheemashankar KULKARNI
-
Patent number: 10745397Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.Type: GrantFiled: July 26, 2016Date of Patent: August 18, 2020Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Dinesh Barawkar, Anil M Deshpande, Santosh Patil, Yogesh Waman, Anil Panmand, Dilip Jadhav, Bheemashankar Kulkarni
-
Publication number: 20200087281Abstract: Fused bicyclic compounds are inhibitors of GPR91. The compounds, their stereoisomers, tautomers, prodrugs, polymorphs, solvates, pharmaceutically acceptable salts, and pharmaceutical compositions containing them are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of GPR91.Type: ApplicationFiled: March 13, 2018Publication date: March 19, 2020Inventors: Nadim SHAIKH, Mahesh THAKKAR, Shailesh SHINDE, Manoj JOSHI, Keshav NAIK, Amit BHALERAO, Mayur MUKIM, Debnath BHUNIYA, Bheemashankar KULKARNI, Kasim MOOKHTIAR
-
Publication number: 20190352442Abstract: The present application relates to a commercially viable process for the preparation of Patiromer, a crosslinked polymer. More particularly the present application relates to a commercially viable process for the preparation of Patiromer sorbitex calcium, an active ingredient useful in the treatment of hyperkalemia.Type: ApplicationFiled: May 9, 2019Publication date: November 21, 2019Inventors: Sivadas Anand, Sarita Mohan Pavaskar, Bheemashankar Kulkarni
-
Patent number: 10435402Abstract: Substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them are disclosed, as well as processes for preparing and using the compounds. These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (RORy). Representative conditions include inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, crythematosus or other disorders.Type: GrantFiled: January 8, 2016Date of Patent: October 8, 2019Assignee: Advinus Therapeutics LimitedInventors: Partha Mukhopadhyay, Yogesh Munot, Nadim Shaikh, Bheemashankar A. Kulkarni, Kasim Mookhtiar
-
Publication number: 20180230098Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: April 13, 2018Publication date: August 16, 2018Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Publication number: 20180215754Abstract: The present invention provides a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof has an EP4 receptor antagonistic action, and is useful as an agent for the prophylaxis or treatment of EP4 receptor associated diseases (e.g., rheumatoid arthritis, aortic aneurysm (e.g. abdominal aortic aneurysm, thoracic aortic aneurysm, thoracoabdominal aortic aneurysm etc.), endometriosis, ankylosing spondylitis, inflammatory breast cancer etc.) and the like.Type: ApplicationFiled: July 26, 2016Publication date: August 2, 2018Inventors: Dinesh BARAWKAR, Anil M DESHPANDE, Santosh PATIL, Yogesh WAMAN, Anil PANMAND, Dilip JADHAV, Bheemashankar KULKARNI
-
Patent number: 9969687Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: GrantFiled: December 22, 2014Date of Patent: May 15, 2018Assignee: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Publication number: 20170362225Abstract: The present disclosure relates to a class of substituted bicyclic compounds of formula (I), their tautomers, polymorphs, stereoisomers, prodrugs, solvates, hydrates, N-oxides, co-crystals, pharmaceutically acceptable salts and pharmaceutical compositions containing them. The disclosure also relates to the process of preparation of compounds of Formula (I). These compounds are useful in the treatment, prevention, prophylaxis, management, or adjunct treatment of all medical conditions related to inhibition of retinoic acid-related orphan receptor gamma (ROR?) such as inflammatory and/or autoimmune disorder, rheumatoid arthritis, psoriasis, psoriatic arthritis, multiple sclerosis, inflammatory bowel disease, allergic diseases, asthma, COPD, cancer, cell proliferation, type 1 diabetes, myasthenia gravis, hematopoetic disfunction, systemic lupus, erythematosus or other disorders.Type: ApplicationFiled: January 8, 2016Publication date: December 21, 2017Inventors: Partha Mukhopadhyay, Yogesh Munot, Nadim Shaikh, Bheemashankar A. Kulkarni, Kasim Mookhtiar
-
Patent number: 9844553Abstract: This invention relates to pyrazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: April 27, 2016Date of Patent: December 19, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Min K. Park, Paul Ratcliffe, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20170073339Abstract: The present application provides novel pyridine compounds and pharmaceutically acceptable salts or prodrugs thereof. Also provided are methods for preparing these compounds. These compounds are useful in inhibiting CYP17 activity by administering a therapeutically effective amount of one or more of the compounds to a patient. By doing so, these compounds are effective in treating conditions associated with CYP17 activity. A variety of conditions can be treated using these compounds and include diseases which are characterized by abnormal cellular proliferation. In one embodiment, the disease is cancer, such as prostate cancer.Type: ApplicationFiled: November 23, 2016Publication date: March 16, 2017Inventors: Roger A. Smith, Nicholas James Laping, Aranapakam M. Venkatesan, Raghava Reddy Kethiri, Chandregowda Venkateshappa, Bheemashankar Kulkarni, Purushottam Dewang, Rajendra Kristam, Rajesh Devraj
-
Patent number: 9567333Abstract: This invention relates to triazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: GrantFiled: October 19, 2015Date of Patent: February 14, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Paul Ratcliffe, Jerry Andrew Taylor, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20170020879Abstract: This invention relates to pyrazolopyridyl compounds of the structural formula: or their pharmaceutically acceptable salts, wherein the variable are defined herein. The inventive compounds selectively inhibit aldosterone synthase. This invention also provides for pharmaceutical compositions comprising the compounds of Formula I or their salts as well as potentially to methods for the treatment, amelioration or prevention of conditions that could be treated by inhibiting aldosterone synthase.Type: ApplicationFiled: April 27, 2016Publication date: January 26, 2017Inventors: D. Jonathan Bennett, Jaiqiang Cai, Emma Carswell, Andrew Cooke, Scott B. Hoyt, Clare London, John MacLean, Min K. Park, Paul Ratcliffe, Yusheng Xiong, Swapan Kumar Samanta, Bheemashankar A. Kulkarni
-
Publication number: 20170001959Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: December 22, 2014Publication date: January 5, 2017Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam
-
Publication number: 20170002011Abstract: The present invention relates to compounds useful as CCR9 modulators, to compositions containing them, to methods of making them, and to methods of using them. In particular, the present invention relates to compounds capable of modulating the function of the CCR9 receptor by acting as partial agonists, antagonists or inverse agonists. Such compounds may be useful to treat, prevent or ameliorate a disease or condition associated with CCR9 activation, including inflammatory and immune disorder diseases or conditions such as inflammatory bowel diseases (IBD).Type: ApplicationFiled: December 22, 2014Publication date: January 5, 2017Applicant: Norgine B.V.Inventors: Rajagopal Bakthavatchalam, Manas Kumar Basu, Ajit Kumar Behera, Chandregowda Venkateshappa, Christopher Alexander Hewson, Sanjay Venkatachalapathi Kadnur, Sarkis Barret Kalindjian, Bheemashankar Kulkarni, Rohit Saxena, Juluri Suresh, Vellarkad Viswanathan, Mohd Zainuddin, Akila Parvathy Dharshinis, Rajenda Kristam